Testing a new drug for advanced solid tumors and blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are able to be up and about (ECOG score 0 or 1).
- You have one of the listed cancers: clear cell kidney cancer, certain types of B-cell lymphoma, or T-cell lymphoma.
- Your cancer has worsened or not responded to at least one previous treatment (two for certain lymphomas).
- You have a tumor that can be measured, and you have a sample of your tumor available for testing.
- You have not had treatment targeting CD70 or a CAR T therapy in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.